Conditions: Neoplasms, Gastrointestinal Tract
Keywords: tumor biopsy capecitabine first line Gastro Esophageal (GE) Junction Cancer Gastric cancer newly diagnosed GE junction lapatinib metastatic or unresectable
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 68
Healthy volunteers: no

Brief summary:
The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.

Detailed description:

Arms:

Interventions: intervention 1: Lapatinib and Capecitabine
Intervention descriptions: intervention 1: oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine

Protocol document: